Skip to main content
SpringerLink
Log in

Pharmacokinetics and toxicity of two modalities of etoposide infusion in metastatic non-small-cell lung carcinoma

  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Summary

The pharmacokinetics and toxicity of two schedules of etoposide administration were studied in 19 patients suffering from metastatic non-small-cell lung cancer. Ten subjects received a 72-h continuous venous infusion (CVI) of 360 mg/m2 etoposide, and nine were given a daily dose of 120 mg/m2 for 3 consecutive days. In the two groups 80 mg/m2 cis-diamminedichloroplatinum (II) (CDDP) was infused on day 1. With CVI, the steadystate plasma concentration was reached 12–24 h after the start of the treatment. The plasma elimination rate showed a biexponential decay curve in both groups. No significant difference between total body clearance and the β-phase volume of distribution was noted between the two modalities of administration. No relationship was found between biological and pharmacokinetic parameters.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Aisner J, Echo DA van, Whitacre M, Wiernik P (1982) A phase I trial of continuous infusion VP16-213 (etoposide). Cancer Chemother Pharmacol 7: 157

    PubMed  CAS  Google Scholar 

  2. Arbuck SG, Douglass HO, Crom WR, Goodwin P, Silk Y, Cooper C, Evans WE (1986) Etoposide pharmacokinetics in patients with normal and abnormal organ origin. J Clin Oncol 4: 1690

    PubMed  CAS  Google Scholar 

  3. Batist G, Carney DN, Cowan KH, Veah SR, Gilliom M, Bunn PA, Ihde DC (1986) Etoposide (VP16) and cisplatin in previously treated small-cell lung cancer: clinical trial and in vitro correlates. J Clin Oncol 4: 982

    PubMed  CAS  Google Scholar 

  4. Bennett CL, Sinkule JA, Schilsky RL, Senekjian E, Choi KE (1987) Phase I clinical and pharmacological study of 72-hour continuous infusion of etoposide in patients with advanced cancer. Cancer Res 47: 1952

    PubMed  CAS  Google Scholar 

  5. Brindley CJ, Antoniw P, Newlands ES, Bagshawe KD (1985) Pharmacokinetics and toxicity of the epipodophyllotoxin derivative (VP16-213) in patients with gestational choriocarcinoma and malignant teratoma. Cancer Chemother Pharmacol 15: 66

    Article  PubMed  CAS  Google Scholar 

  6. Canal P, Michel C, Bugat R, Soula G, Carton M (1986) Quantification of teniposide in human serum by high performance liquid chromatography with electrochemical detection. J Chromatogr 375: 451

    Article  PubMed  CAS  Google Scholar 

  7. Clark PI, Slevin ML (1987) The clinical pharmacology of etoposide and teniposide. Clin Pharmacokinet 12: 223

    Article  PubMed  CAS  Google Scholar 

  8. Creagan ET. Richardson RL, Kovach JS (1988) Pilot study of a continuous five-day intravenous infusion of etoposide concomitant with cisplatin in selected patients with advanced cancer. J Clin Oncol 6: 1197

    PubMed  CAS  Google Scholar 

  9. Dhingra HM, Valdivieso M, Booser DJ, Umsaxasdi T, Carr DT, Chuiten DF, Murphy WK, Issel BF, Spitzer G, Farha P, Dixon C (1984) Chemotherapy for advanced adenocarcinoma and squamous cell carcinoma of the lung with etoposide and cisplatin. Cancer Treat Rep 68: 671

    PubMed  CAS  Google Scholar 

  10. D’Incalci M, Rossi C, Zuchetti M, Urso R, Cavalli F, Mangioni C, Willems Y, Sessa C (1986) Pharmacokinetics of etoposide in patients with abnormal renal and hepatic function. Cancer Res 46: 2566

    PubMed  CAS  Google Scholar 

  11. Edwards CM, Glisson BS, King CK, Smallwood-Kentro S, Ross WE (1987) Etoposide-induced DNA cleavage in human leukemia cells. Cancer Chemother Pharmacol 20: 162

    Article  PubMed  CAS  Google Scholar 

  12. Gomeni C, Gomeni R, Rowland M (1978) IG-Pharm: an interactive graphic package for pharmacokinetic analysis. Comput Biomed Res 11: 345

    Article  PubMed  CAS  Google Scholar 

  13. Gouyette A, Deniel A, Pico JL, Droz JP, Baume D, Ostronoff M, Bail N Le, Hayat M (1987) Clinical pharmacology of high-dose etoposide associated with cisplatin. Pharmacokinetic and metabolic studies. Eur J Cancer Clin Oncol 23: 1627

    Article  PubMed  CAS  Google Scholar 

  14. Hsiang YH, Wu HY, Liu LF (1988) Topoisomerases: novel therapeutic targets in cancer chemotherapy. Biochem Pharmacol 37: 1801

    Article  PubMed  CAS  Google Scholar 

  15. Joss RA, Alberto P, Obrecht JP, Barrelet L, Holdener EE, Siegenthaler P, Goldhirsch A, Mermillod B, Cavalli F (1984) Combination chemotherapy for non-small-cell lung cancer with doxorubicin and mitomycin or cisplatin and etoposide. Cancer Treat Rep 68: 1079

    PubMed  CAS  Google Scholar 

  16. Kalminsky DK, Look AT, Ducore J, Fridland A (1983) Effects of the epipodophyllotoxin VP16-213 on cell cycle traverse, DNA synthesis and DNA strand size in cultures of human leukemic lymphoblasts. Cancer Res 43: 1592

    Google Scholar 

  17. Klastersky J (1985) VP16 and cisplatin in the treatment of non-small-cell lung cancer. Semin Oncol 12: 17

    PubMed  CAS  Google Scholar 

  18. Klastersky J (1986) Therapy with cisplatin and etoposide for non-small-cell lung cancer. Semin Oncol 13: 104

    PubMed  CAS  Google Scholar 

  19. Longeval E, Klastersky J (1982) Combination chemotherapy with cisplatin and etoposide in bronchogenic squamous cell carcinoma and adenocarcinoma. Cancer 50: 2751

    Article  PubMed  CAS  Google Scholar 

  20. Matsushima Y, Kanzawa F, Hoshi A, Shimizu E, Nomori H, Sasaki Y, Saijo N (1985) Time-schedule dependency of the inhibiting activity of various anticancer drugs in the clonogenic assay. Cancer Chemother Pharmacol 14: 104

    Article  PubMed  CAS  Google Scholar 

  21. Schabel FM Jr, Trader MW, Laster WR Jr, Corbett TH, Griswold DP Jr (1979)cis-dichlorodiammineplatinum(II): combination chemotherapy and cross-resistance studies with tumors of mice. Cancer Treat Rep 63: 1459

    PubMed  CAS  Google Scholar 

  22. Sinkule JA, Hutson P, Hayes A, Etcubanas E, Evans W (1984) Pharmacokinetics of etoposide (VP16) in children and adolescents with refractory solid tumors. Cancer Res 44: 3109

    PubMed  CAS  Google Scholar 

  23. Slevin ML, Clark PI, Joel SP, Malik S, Osborne RJ, Gregory WM, Lowe DG, Reznek RH, Wrigley PFM (1989) A randomized trial to evaluate the effect of schedule on the activity of etoposide in small cell lung cancer. J Clin Oncol 7: 1333

    PubMed  CAS  Google Scholar 

  24. Sorensen JB, Hansen HH (1988) Combination chemotherapy for advanced adenocarcinoma of the lung. A review. Cancer Chemother Pharmacol 21: 103

    PubMed  CAS  Google Scholar 

  25. Splinter T, Kok T, Kho S, Lameris H, Kate F Ten, Dalesio O, Dolman B, Palmen F, Bouvy J, Burghouts J, Simonis F, Harper P, Rankin E, Reijswoud I van, Hoogenhuijze J van (1988) A multicenter phase II trial of cisplatin and oral etoposide (VP16) in inoperable non-small-cell lung cancer. Semin Oncol 13: 97

    Google Scholar 

  26. Tschopp L, Fliedner VE von, Sauter C, Maurice P, Gratwohl A, Fopp M, Cavalli F (1986) Efficacy and clinical cross-resistance of a new combination therapy (AMSA/VP16) in previously treated patients with acute nonlymphocytic leukemia. J Clin Oncol 4: 318

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Départements de Biologie Clinique et d’Oncologie Médicale, Centre Claudius Regaud, 20-24, rue du Pont Saint-Pierre, F-31052, Toulouse Cedex, France

    Etienne Chatelut, Christine Chevreau, Evelyne Blancy, Anne Lequellec, Pierre Canal, Henri Roche & Roland Bugat

  2. Université Paul Sabatier, 118 route de Narbonne, F-31062, Toulouse, France

    Etienne Chatelut, Evelyne Blancy, Georges Houin & Roland Bugat

  3. Unité de Pharmacocinétique, CHR PURPAN, F-31059, Toulouse Cedex, France

    Georges Houin

Authors
  1. Etienne Chatelut
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christine Chevreau
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Evelyne Blancy
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Anne Lequellec
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Pierre Canal
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Henri Roche
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Georges Houin
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Roland Bugat
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

This work was supported by a grant from the Comité Départemental de la Haute Garonne de la Ligue Nationale de Lutte Contre le Cancer

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chatelut, E., Chevreau, C., Blancy, E. et al. Pharmacokinetics and toxicity of two modalities of etoposide infusion in metastatic non-small-cell lung carcinoma. Cancer Chemother Pharmacol 26, 365–368 (1990). https://doi.org/10.1007/BF02897295

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02897295

Keywords

Search

Navigation